Industries > Pharma > Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2018-2028

Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2018-2028

Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators, Biologics, Crohn’s Disease, Ulcerative Colitis

PUBLISHED: 29 May 2018
PAGES: 196
PRODUCT CODE: PHA0312
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
DOWNLOAD SAMPLE
SKU: PHA0312 Categories: , Tags: , ,

The global inflammatory bowel diseases (IBD) drug market is estimated at $6.7bn in 2017 and $7.6bn in 2023. Biologic therapies held 57% share of the IBD market in 2017. The antibiotics segment of the IBD market is estimated to grow at a CAGR of 6.3% from 2018-2023.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 196-page report you will receive 141 charts– all unavailable elsewhere.

The 196-page report provides clear detailed insight into the global inflammatory bowel diseases (IBD) drug market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Global Inflammatory Bowel Diseases (IBD) Drug Market forecasts from 2018-2028

Submarket forecasts from 2018-2028:
• Biologics
• Aminosalicylates
• Antibiotics
• Corticosteroids
• Immunomodulators

Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2018-2028

• Revenue forecast from 2018-2028 for 17 leading products:
• Humira
• Remicade
• Lialda
• Asacol
• Pentasa
• Xifaxan
• Cimzia
• Tysabri
• Simponi
• Canasa/Salofalk
• Entyvio
• Apriso
• Medrol
• Neoral
• Entocort
• Uceris
• Azulfidine

• Revenue forecasts from 2018-2028 for 11 countries:
• US
• Japan
• Germany, France, UK, Spain and Italy (EU5)
• Brazil, Russia, India and China (BRIC)

• Discussions on research and development, including drug candidates in these classes:
• Interleukin (IL) inhibitors
• Cell-adhesion molecule (CAM) inhibitors
• TNF-alpha inhibitors
• Stem cell therapies
• JAK inhibitors
• Toll-like receptor agonists

• Assessment of selected leading companies that hold major market shares in the inflammatory bowel diseases drug industry

• Discussions on trends in the industry and assesses strengths and weaknesses, as well as opportunities and threats (SWOT). It also analyses social, technological, economic and political factors (STEP) that influence the IBD market. Moreover, this report discusses factors that drive and restrain the IBD market.

Visiongain’s study is intended for anyone requiring commercial analyses for the Global Inflammatory Bowel Diseases (IBD) Drug Market. You find data, trends and predictions.

Buy our report today Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2018-2028: Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators, Biologics, Crohn’s Disease, Ulcerative Colitis.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2018-2028


Download sample pages

Complete the form below to download your free sample pages for Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2018-2028


Latest Pharma news

“Biological Drug API Manufacturing market set to grow to $11bn by 2025” says Visiongain report

Strengths in the biotech contract manufacturing market, from the perspective of the CMOs, stem from the demand for lower cost manufacturing from companies of all sizes.

07 November 2019

READ

“global radiation oncology market is anticipated to surpass USD 6.5 billion by 2020”, says Visiongain

Growing aging population, urbanization, and growing wealth in low- and middle-income countries such as China and India are anticipated to boost the APAC radiation oncology market.

07 November 2019

READ

“Global Rabies Diagnostics Market is anticipated to surpass USD 1.8 billion by 2020”, says Visiongain

Several international healthcare organizations are working with healthcare organizations to develop and market new detection assays to drive efforts aimed at fighting the disease.

07 November 2019

READ

“Global spinal muscular atrophy (SMA) market is anticipated is to surpass USD 950 Million by 2020”, says Visiongain

Increasing awareness of SMA and increasing numbers of programs to expand treatment options for rare diseases are key factors that are boosting the market growth.

07 November 2019

READ

Categories

Category